VolitionRx Signs LOI with Missionpharma to explore the Development and Launch of Volition's Lateral Flow Technology for NETosis Worldwide

An estimated 2.3 million newborns die yearly. VolitionRx and Missionpharma explore a finger-prick newborn sepsis test.

VolitionRx Limited Announces $500,000 Partial Pre-Payment of Convertible Note in Cash

VolitionRx Executes Non-Binding Letter Of Intent With Missionpharma A/S To Develop, Roll Out Volition's Prototype Lateral Flow Technology For NETosis

VolitionRx Makes $500K Cash Partial Prepayment Towards Outstanding Principal Balance On Its Senior Secured Convertible Promissory Note

VolitionRx Participates in Launch of DETECSEPS Program in France

VNRX: VolitionRx Prepays Outstanding Balance on the $7,500,000 Lind Senior Secured Convertible Promissory Note Dated May 20, 2025. Review of Papers, Posters, and Videos Released in Mid-2026. Sysmex Collaboration is the 3rd Recent Agreement in the Human Space.

VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027

Lagoda Investment Management, L.P. Adds VolitionRX Ltd (VNRX) -- Shares Look 98% Undervalued on GF Value

Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations

VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets

Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis

Volition (VNRX) Q2 2026 Earnings Call Transcript

Earnings To Watch: VolitionRX Ltd (VNRX) Q2 2026 -- GF Value Sees 3914% Upside

VNRX Forecast — Price Target — Prediction for 2027